2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - New Orleans Theatre B
From Tumor Evolution to Therapeutic Targets: Integrated Genomic and Microenvironmental Insights in B-Cell Lymphomas
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Pathogenesis, Genomics, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

391 Isoform-resolved immunogenomics reveals shared, tumor-restricted HLA ligands and actionable T-cell targets in B-cell non-Hodgkin lymphoma

Dustin McCurry, MD, Chunlei Yu2, Juline Deppen, PhD3, Arnau Peris Cuesta4, Bohu Pan5, Aya Albittar, MD6, Beatriz Alvarado Hernandez, PhD7, Kuhu Rai8, Juan Gallegos9, Meredith Brienen10, Loretta Nastoupil, MD11, Jean Koff, MD, MSc12, Luis Malpica, MD13, Christopher R. Flowers Jr, MD, MS14, Sachet Shukla, PhD15
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 The University of Texas MD Anderson Cancer Center, Houston, United States
7 The University of Texas MD Anderson Cancer Center, Houston, United States
8 The University of Texas MD Anderson Cancer Center, Houston, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 CommonSpirit Medical Oncology, Durango, Colorado, United States, The University of Texas MD Anderson Cancer Center, Houston, United States
12 Emory University, Atlanta, Georgia, United States
13 The University of Texas MD Anderson Cancer Center, Houston, United States
14 The University of Texas MD Anderson Cancer Center, Houston, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
T-cell immunotherapies targeting normal B-cell antigens (CD19, CD20, CD22, CD79b) have transformed the treatment of B-cell non-Hodgkin lymphoma (B-NHL), establishing its exquisite sensitivity to T-cell therapies. However, antigen loss drives resistance in 30-80% of patients and infection due to normal B-cell aplasia remains the leading cause of non-relapse mortality. Critically, no B-NHL-restricted targets have been defined. We hypothesized that alternative splicing driven by B-NHL oncogenic programs generates tumor-restricted HLA ligands detectable by long-read sequencing, yielding targets that bypass antigen loss and spare normal B cells.

We performed HLA-I and HLA-II immunopeptidomics, HLA flow cytometry, whole-exome, short-read (srRNA) and long-read (lrRNA) RNA-sequencing on 27 B-NHL samples [HGBCL n=2; DLBCL, GCB n=9; DLBCL, ABC n=7, DLBCL, NOS n=8, BL n=1], with an end-to-end pipeline to call mutations, assemble isoforms, search mass spectra at 1% FDR, type HLA, and assign peptide-HLA restriction. Layered normal filtering used Swiss-Prot, the HLA Ligand Atlas (>1,200 normal immunopeptidomes) and normal srRNA (GTEx) and lrRNA (ENCODE4) transcriptomes. Immunogenicity was tested with a clinical-grade antigen-specific T-cell protocol (NCT06483048); products were assessed for tumor cytotoxicity, and single-cell TCR-seq of CD137+ cells recovered TCRs counter-screened against HLA-matched normal lymphocytes.

Surface HLA-I was detectable in 27/27 samples (100%), including those with lesions repressing HLA-I (EZH2 n=4; HLA-A del n=2; HLA-B del n=1). HLA-II was detectable in 23 samples (85%); HLA-II-negative cases carried CREBBP (n=2) or EP300 (n=1) mutations. Dominant restrictions were A*02:01 (n=9), A*03:01 (n=8), A*01:01 (n=8), C*07:01 (n=7), and B*40:01 (n=5). lrRNA and srRNA yielded equivalent total HLA-I presented peptides (p=0.75), but lrRNA recovered significantly more tumor-specific, isoform-dependent peptides (p=0.04). Only 1 HLA-I peptide across the entire cohort arose from a somatic mutation, establishing that mutational neoantigens are insufficient in B-NHL and motivating non-mutational sources.

We identified 452 tumor-specific, HLA-resolved peptides shared across samples (>=2 immunopeptidomes; >=75% of cohort transcriptomes). Stringent transcriptional filtering (max CPM <15 in any normal tissue including normal B cells and >2 log2FC enrichment in B-NHL) retained 116 shared peptides, with >=1 peptide restricted to each of the 15 most common HLA alleles. Source isoforms included kinetochore components, cancer-testis antigens, AICDA, EZH2 and MELK, and a novel A*02:01 ligand from an isoform of BIRC5 (Survivin), a target of late-stage peptide vaccines; this ligand was transcriptionally present in 26/27 samples (96%), enriched in B-NHL (log2FC 3.17), and absent from all normal immunopeptidomes. In HLA-II immunopeptidomics (n=20), 13 samples (65%) presented at least one clonal mutant immunoglobulin neoantigen from CDR3 and FR3 regions, indicating that HLA-II display of the clonal Ig sequence is a conserved feature of B-NHL.

For an A*02:01 ligand from a novel SAE1 isoform, immunogenicity was confirmed in 3 independent donors by antigen-specific cytokine production (p<0.001 vs no-antigen control). Induced T cells preferentially lysed an A*02:01 B-NHL line derived from CAR-T-refractory disease relative to CMV-specific effectors (p<0.05 at 1:1 and 2:1 E:T). sc-TCR-seq of CD137+ cells recovered a TCR that recognized mono-allelic A*02:01 lines expressing the antigen but not HLA-matched normal lymphocytes. Clonal Ig-derived antigens were also immunogenic and preferentially recognized by CD4+ T cells (p<0.05). Immunogenicity validation is ongoing.

Long-read immunopeptidogenomics defines the first tumor-restricted HLA ligandome of B-NHL, nominating 116 shared, normal-filtered targets spanning the most common HLA alleles, plus a conserved class of clonal immunoglobulin HLA-II neoantigens. Functional validation of a splice-isoform ligand, including lysis of CAR-T-refractory lymphoma and recovery of a non-cross-reactive TCR, establishes these targets as actionable for vaccines, bispecifics, and cellular therapy that could remain effective despite CD19 antigen loss while sparing the normal B-cell compartment. Because clinically actionable MRD assays already resolve the clonal immunoglobulin sequence, HLA-II neoantigens can be nominated for each patient from existing clinical-grade data, providing a direct path to vaccine trials.
Dustin McCurry, MD: No relevant conflicts of interest to declare.